Filing Details

Accession Number:
0000899243-20-013395
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-18 16:45:20
Reporting Period:
2020-05-14
Accepted Time:
2020-05-18 16:45:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1326190 Altimmune Inc. ALT Pharmaceutical Preparations (2834) 202726770
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1802702 Velocity Pharmaceutical Holdings Llc 400 Oyster Blvd., Suite 202
South San Francisco CA 94080
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-05-14 169,378 $4.81 1,717,872 No 4 S Direct
Common Stock Disposition 2020-05-15 30,622 $4.65 1,687,250 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.65 to $5.02. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
  2. The shares are directly held by Velocity Pharmaceutical Holdings LLC ("VPH"). Velocity Pharma Management, LLC ("VPM") is the manager of VPH. David J. Collier and James F. Watson are the managing members of VPM, and as such may be deemed to hold shared voting and dispositive power over the shares held by VPH. Mr. Collier and Mr. Watson disclaim beneficial ownership of the shares held by VPH except to the extent of their pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 to $4.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.